HomeCompareELOX vs PLD

ELOX vs PLD: Dividend Comparison 2026

ELOX yields 2475.25% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ELOX wins by $73382614255.27M in total portfolio value
10 years
ELOX
ELOX
● Live price
2475.25%
Share price
$0.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$73382614261.78M
Annual income
$67,980,042,160,694,380.00
Full ELOX calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — ELOX vs PLD

📍 ELOX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodELOXPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ELOX + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ELOX pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ELOX
Annual income on $10K today (after 15% tax)
$210,396.04/yr
After 10yr DRIP, annual income (after tax)
$57,783,035,836,590,220.00/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, ELOX beats the other by $57,783,035,832,122,260.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ELOX + PLD for your $10,000?

ELOX: 50%PLD: 50%
100% PLD50/50100% ELOX
Portfolio after 10yr
$36691307134.14M
Annual income
$33,990,021,082,975,412.00/yr
Blended yield
92.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

ELOX
Analyst Ratings
8
Buy
3
Hold
Consensus: Buy
Altman Z
-94.4
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ELOX buys
0
PLD buys
0
No recent congressional trades found for ELOX or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricELOXPLD
Forward yield2475.25%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$73382614261.78M$6.50M
Annual income after 10y$67,980,042,160,694,380.00$5,256,436.18
Total dividends collected$73004868605.64M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: ELOX vs PLD ($10,000, DRIP)

YearELOX PortfolioELOX Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$258,225$247,524.75$11,255$555.24+$247.0KELOX
2$6,249,854$5,973,553.08$13,062$1,018.59+$6.24MELOX
3$141,807,743$135,120,399.71$15,903$1,926.67+$141.79MELOX
4$3,017,015,462$2,865,281,177.24$20,839$3,823.32+$3016.99MELOX
5$60,200,153,348$56,971,946,803.11$30,464$8,166.08+$60200.12MELOX
6$1,126,836,870,511$1,062,422,706,429.18$52,054$19,457.30+$1126836.82MELOX
7$19,791,333,921,123$18,585,618,469,676.22$109,886$54,188.93+$19791333.81MELOX
8$326,252,175,090,930$305,075,447,795,328.50$304,030$186,451.18+$326252174.79MELOX
9$5,049,132,804,749,982$4,700,042,977,402,686.00$1,166,125$840,813.32+$5049132803.58MELOX
10$73,382,614,261,776,860$67,980,042,160,694,380.00$6,504,190$5,256,436.18+$73382614255.27MELOX

ELOX vs PLD: Complete Analysis 2026

ELOXStock

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.

Full ELOX Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this ELOX vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ELOX vs SCHDELOX vs JEPIELOX vs OELOX vs KOELOX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.